PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2092653
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2092653
Pharmaceutical Glass Packaging Market size was valued at US$ 22,987.89 Million in 2025, expanding at a CAGR of 10.6% from 2026 to 2033.
Pharmaceutical glass packaging is any type of glass container used in storing, protecting, transporting, and dispensing of pharmaceuticals safely, without compromising on their sterility, efficacy, stability, and safety for their entire shelf life. Such glass packaging containers are made from pharmaceutical grade glass, which includes either Type I or borosilicate, Type II treated soda lime, or simply Type III soda lime glass. The main advantages that make such types of pharmaceutical glass containers desirable are their chemical resistance, lower extractables, high barrier characteristics, and compatibility with various drugs.
Pharmaceutical Glass Packaging Market- Market Dynamics
Increasing demand for injectable drugs and biologics to propel market demand
Increasing demand for injectable drugs and biologics is a key factor driving growth in the pharmaceutical glass packaging industry due to their necessity for packaging which is non-reactive, sterile, and chemically resistant. Pharmaceutical glass packaging in the form of Type I borosilicate glass vials, ampoules, cartridges, and prefilled syringes is considered to be the preferred packaging for biologics, monoclonal antibodies, vaccines, insulin and other injectable drugs due to the reduced risk of chemical reactions and contamination. Increasing development and use of biological therapies from leading pharmaceutical firms is causing an increasing demand for pharmaceutical glass containers. As there is an increasing number of injectable biological drugs in clinical trials and production, there is also increasing demand for glass packaging.
For instance, total revenues hit a record high for Amgen Inc. of USD 33.4 billion in 2024, growing 19% compared to the previous year, which was mainly due to higher demand for injectable biologic medications. A number of biologics showed good sales growth performance in 2024, such as Repatha(R) (36% full year sales), TEZSPIRE(R) (71%), EVENITY(R) (35%) and BLINCYTO(R) (41%). All of these products are packaged using glass vials, prefilled syringes, or cartridges, directly supporting demand for glass packaging.
The Global Pharmaceutical Glass Packaging Market is segmented on the basis of product type, material type, manufacturing process, application, end use, and region.
The market is divided into four categories based on material type: Type I Glass, Type III Glass, Type II Glass and Amber Glass. The Type I Glass segment dominates the market. This growth has been possible on account of the greater chemical resistance, higher temperature stability, and suitability for highly sensitive pharmaceutical formulation that this type of glass offers. The Type I Borosilicate Glass is ideal for pharmaceutical packaging of injectables, biopharmaceuticals, vaccines, monoclonal antibodies, gene therapies, biosimilars, and other such high-value pharmaceuticals due to the minimal interaction that occurs between the drug and the packer.
Pharmaceutical Glass Packaging Market- Geographical Insights
North America makes up a considerable portion of the pharmaceuticals glass packaging market, owing to the presence of a huge pharmaceutical & biotech industry, rising manufacture of injectable products & biopharmaceuticals, rising capabilities in vaccine manufacture, and high regulatory requirements concerning pharmaceutical packaging. The presence of key pharmaceutical companies, CDMOs (Contract Development & Manufacturing Organizations), and top glass packaging providers is also contributing to consistent regional income growth.
US Pharmaceutical Glass Packaging Market- Country Insights
The USA is the major player in revenue generation in the Pharmaceutical Glass Packaging market owing to its dominant pharmaceutical and biotech industry, production of injectable products, extensive research and development (R&D), and production of vaccines and specialty products. The more there is production in the pharmaceutical sector, the greater will be the demand for pharmaceutical glass packaging in the form of vials, ampoules, cartridges, bottles, and pre-filled syringes. For instance, Johnson & Johnson reported Innovative Medicine sales of USD 57.1 billion in 2024, an increase of approximately 4% year over year, driven by strong demand for injectable oncology, immunology, and specialty medicines.
The Pharmaceutical Glass Packaging industry can be considered moderately consolidated, with a number of global glass packaging providers having considerable market shares on the basis of revenue globally. Competition in the industry revolves around innovation, product quality, production capability, compliance, reliability of supplies and long-term relationships with pharma and biotech organizations. The competition in this industry is based on providing high-quality Type I borosilicate glass, low delamination glass vials, coated glass packaging containers, and ready-to-use sterile packaging for injectables.
In May 2025, SCHOTT Pharma, a pioneer in drug containment and delivery solutions, announced that TPG, a leading global alternative asset management firm, has entered into a binding agreement to acquire a 35% stake in its joint venture SCHOTT Poonawalla from Serum Institute of India (SII).
In October 2024, Nipro PharmaPackaging, a specialist in glass tubing, glass primary packaging, and medical devices, announced the launch of its innovative D2F (Direct-to-Fill) glass vials. These vials, featuring Stevanato Group's advanced EZ-fill technology, offer a high-quality ready-to-use (RTU) solution designed to meet the rigorous standards and increasing requirements of the pharmaceutical industry.